Oh, do we have some good opportunities? Juicy opportunities, folks. In this video, we are going to be talking about the top seven penny Stocks for August 2020. But Charlie Really? Penny stocks? Uh, think of the children. Well, we make these videos once per month every month and the way that we make these is we present catalysts and then we present strategies to take advantage of the catalysts.

One of the reasons that we include penny stocks in our trading is because if you have a small no name company and you have a big event catalyst, then all of a sudden you have a lot of fluctuation. These catalysts come in the form of Fda approvals, insider trading activity, earnings announcements, and so forth. But folks remember that at the end of the day what I do is I present battlefields. These tickers are battlefields, so I can present all of the battlefields that I want.

and I could talk about the different risks involved with that specific battlefield. But if you're not personally preparing to go out into battle, you're going to have a bad time and we do not want you to have a bad time. But anyways, folks, let's go ahead and talk about last month's picks, what happened last month. Okay, so in last month's Top Penny Stocks video, we called out Uavs.

At the time, rumors were spreading that Uavs was going to partner with Amazon for their drone program. As traders, though our motto is to not give a hoot about whether or not rumors are true, but just to take advantage of the moves that come as a result of these rumors. So we called out Uavs at 159 and it ran up to highs at 392.. If you want to learn more about how I found this particular play, I actually made a whole video called my 150 plus penny stock, which you could find on the main channel page.

Next, we called out Bbby. It had gotten beaten down on bad news, but since every reaction is a dirty overreaction, it recovered over the next few weeks. Next we call that Virca Vrc8. Now this was an interesting play.

It actually ran up ten percent the day after we called it out, but then sold off the rest of the month. Very clean run though on the first day. Overall though, the concentration of the opportunity was really just the first day after we called it out. Next, we called out Osmt.

Now, Osmt was due for an Fda approval, but it had already gotten that approval and ran up. But amongst other factors, Osmt had not reacted in the way that was due for previous price action and previous behavior. So we called it out at seven dollars and the next day it ran up cleanly to 967 before validating out and selling off. Lastly, we called out Enz.

We talked about how every time Enz runs up on hype, it gets beat down and then has subsequent runs. But we pointed it out when it was trading at 271 and the next session it ran up to over 3 30.. But anyways, what you should know about all these picks is that they have two different components. There's the catalyst and then there's the charts.

The catalyst tells you what is motivating the charts and then the chart tells you where to enter and exit. This is important because as traders, we don't just randomly buy and hold stocks. That is something that little babies do. If you're a little baby, you go Google.

Let Me Just hold this stock. If you just laughed at that thinking this is a joke, well you're a joke because at the end of the day there's nothing funny about holding a losing position. Folks, please do Not hold in hope of stocks. Especially penny stocks.

If you're going to hold and help with something, at least do it with like Apple or Tesla. Well not Tesla, but Apple. But anyways, folks, the one time that holding and hoping is okay is when you hold and hope that ravishing like button. But the thing is that once you take your finger off the like button, hey you know you don't have to hope anymore because it's ravishing.

Okay and quick plug for folks who are wondering what broker to trade these stocks on. We always like to send new traders over to Weeble, comes to Weibo. We have really great features such as your pre-market gainers, your after hours runners. You're most active.

There's just tons and tons of just really simplistic but also powerful tools to get you started trading. And of course if you sign up with our link in the description below, you will get not one but two free stocks. So as always, if you are broke or curious, you might as well check them out. Now, Trvn will be having their Fde approval decision on August 7th for their drug that treats acute pain.

But speaking of acute pain, let me make you acutely aware of the situation here. We've already run up multiple hundred percentage points since March, so this isn't your typical Fda approval play that gets an approval out of nowhere and then runs up like 2 000. This is a company that has been gaining steam all year. The monkey analyst firm that ranked it is still staying consistent with it and giving it upside to 350 which is still another 56 percent of upside.

But to really understand how Trv is going to trade, you have to understand the drug that's up for approval only. Ceredine This is a drug that was originally slated for approval back in late 2018. In the run-up to that Fda approval decision, Trvn had nearly doubled, but then the Fda decided to disapprove it and the price got beat down massively. Well, it wasn't really a disapproval so much as it was a crl delay.

but nonetheless, after it got beat down like a rabid dog, Trvn was pretty quiet. Now in 2020, we've seen this consistent run up now that this drug is once again in the running for approval very very soon on August 7th, and the last time investors thought this drug was going to get approved, it ran to 358. So it's not crazy to say that there's a lot of upside potential if it does get another approval. And it is also worth noting that a another disapproval or delay would likely cause an even worse reaction this time around because it would make investors lose hope in the future of this drug and all of the money that went into its development.

Because obviously companies pour oodles and oodles of money and also poodles of money into these drugs. So if they don't work out, if they don't actually make it to the market and make profit, all that money is down the tubes. And it is also worth noting that I'm not the biggest fan of buying stocks after they've already run up so much because that means they could have already pre-factored in a lot of the news. But on the other hand, we aren't trading that much higher than we were just a short while ago when investors had grown to accept that this drug had got declined.

So the key with this is continued pre-anticipatory runs as we get closer to the date. If we don't get the runs that we want, who cares, stay out. We can always play the post reaction. Okay iton Eton.

So Eton will be having their Fda approval decision for their drug Em-100 This was originally slated for July 12th, but it got delayed to August 10th. Eton's actually been winning quite a bit lately. It was up on a federal contract, then it was up on new drugs added to their pipeline, and a slew of other events that led to the price action consistently going up. Now, this is one of the few positions in the penny stock realm that trades very, very smoothly, at least for what it is.

And that's because it has a lot of other drugs in their pipeline. It has a lot of stability that's not just all wrapped around one drug. And when you look at price targets long term, this reflects that. We see these intense price targets to 1433, which is over 100 of upside seemingly factoring in approvals.

But folks, let the monkey analyst just be the monkey analysts. We don't trust the monkeys. Too many people treat trading as fortune telling. Anybody that tells you oh so-and-so stocks going to be trading at this price point in a year or at this price point in two years? Well, they're probably morons.

And then because there's so many of these morons. Eventually, when the price gets there, everyone's like, hey, that guy called out the price target because some of the morons are gonna get it right and then everyone will say, oh my god, that analyst, He's a genius. Maybe if by genius you mean genus, then yes, that. That is what I'd characterize them as.

okay. Next, Tcda. Now, Tcda is in the running for their approval on their drug for chronic kidney Disease. This decision will be made on August 22nd, but a few weeks ago, Tcda got a notification from the Fda saying that there were issues with the labeling for their drugs and they needed to work these out.

but they didn't give a lot more information as to what this meant and what this meant for the approval. which led investors to speculate that as we get closer to this approval, that everything's just gonna fall through the cracks. And that's why Tcda got beat down like a rabid dog. But here is where the opportunity is.

You see, the sell-off provides a unique opportunity to get a good entry point if and only if we start seeing pre-anticipatory runs or good news. This is that sort of play that already has given away a lot of its downside, but now has so much added upside that if the news is actually good, it's going to be a fantastico opportunity. Think about it, if we were trading up here and we hadn't gotten this news, then there wouldn't have been as much upside. And yeah, some of these Fda approvals can run like hundreds of percent over, but at least if you're being conservative, you're saying okay.

well, at least pre-crisis highs. But in this situation that we're in, we've got tons of upside just to get back to where we were trading before this bad news even came out, so we could see that conservatively speaking, we've got a lot of upside if we do get good news. But at Ziptrader we're never raunchy. Raccoons.

Okay, maybe raunchy. And again, going back to what the Fda said that caused this beatdown. Well, the Fda said that this does not reflect this news, does not reflect a final decision on this drug. And honestly, at the end of the day, this is still a drug that was accepted under the Fda's accelerated approval program.

So best case scenario: we get an approval. Worst case scenario: we get an affirmation of what we already think is going to happen What most people already think is going to happen, which is bad news. So this is essentially a situation where the best case scenario is much better than the worst case scenario is bad. I hope that makes sense.

By the way, if you are having a hard time keeping up to date with all these different picks, then obviously you would because the market changes every day and there's just like tons and tons of different tickers that you need to watch and you're probably missing out on all the best plays like Kodak. And you know, all those guys that we had on our nightly watch lists. So if you're missing out on all of these plays, you want to make sure that you're in Zip Trader Circle. We post nightly watch lists there every night and you have a ton of other traders that would love to have you on board and answer any questions that you may have within Zip Trader Circle.

This is our free Facebook group and I'll put the link below if you'd like to join. Okay, next Lpcn Now Lpcn will be having their Fda approval for men with low testosterone the Big low T boys. But for context on the chart. Context though, Lpcn's trading price got totally destroyed, it went from 282 over-reaction lows at around 35 cents.

This is one of the worst Beatdowns I've seen since I went to the Beatdown Palooza. But what was the bad news that caused this? Well, the bad news was that this was the very same drug which had gotten a Crl letter which basically meant it got delayed and that's where we are today. On to the second try. But this Beatdown is really telling.

You can tell how much a company depends on a drug's success by looking at how quickly it reacts to news, and if it can react this massively to bad news, it can definitely react just as massively, if not more massively to good news. Because at the end of the day, investors here still had hopes that it was going to get approved and it likely would have ran up even more if it had gotten approved. but it didn't. It got delayed and thus it got beat down.

So just to return to where it was when folks thought it was going to get approved would put us back here Almost twice the current value and we've seen a pre-anticipatory run as investors start speculating on approval. And I'd like to play continued price strength as we get closer. and if we get an approval. Bam, we have an opportunity.

Okay, next F-e-n-c will be having their Fda approval date on August 10th, 2020. this is for their hearing loss treatment. Fenc has a pattern of running up, overheating, and then cooling off. Obviously common sense is that it's better to take advantage When it's cooling off, there's no need to overpay.

We as traders are cheap, and as always our monkey analysts are giving wacky price targets over 100 of Upside. It's actually hilarious. But a lot of people look at these price targets and say, oh hey, that means it has to go up that much. No folks, these monkeys just come with insane price estimates that get them attention.

It's like a monkey throwing bananas at onlookers. Key with this and any Fda reaction play is to get a good deal and play off a pre-anticipatory run. Okay, next Otlk. Now Otlk will be having their phase data release in August 2020.

now we don't have an exact date on which this is going to be happening, which is why I've put it at the end of the video. But since we are in a period of cooling off, approaching the dropping of phase data, it's a unique opportunity to play heightened upside with perhaps a fun, pre-anticipatory running setup. In terms of insider buys, we've been getting a lot of positive inflow for the last year. Of course, the numbers of insider purchases really aren't that high.

A twenty thousand dollar investment on the part of this guy isn't really that much. When you're considering that he probably makes like five hundred thousand a year, you know what? Let's let's fact check that I wanna see how much he makes. Okay, so a quick Google search pulls up the fact that he makes 1.8 million in total compensation, and he invested 20 000 of that in the company. Now, obviously, some of his compensation is likely from stock options, so it's a little bit more complex than that.

But at the end of the day, 20 000 isn't very much for insider activity, but if you look at institutional holders, we've got net inflowing of big names since the end of March. These institutions are massively massively increasing their positions, and this is a huge elevating factor. So the institutional holders believe in the company, and this is something that at least creates some more stability for when we're approaching the setup. Okay, and lastly, Dvax.

Now, Dvax is working on starting trials for a vaccine, but it isn't one of the biggest players so I don't want to go too much into this. It's just the fact that we have patterns of spikability on news and the fact that anything in terms of vaccines and stocks that have previous patterns of spikability are worth watching for trading said spikability. But anyways, folks, please do me one last favor if you've watched this video to the end. which I know if you've watched the video to the end, you're one of the more dedicated people who are actually interested in trading.

Or maybe you just think I'm a buffoon and you like watching me make fun of myself. But if you've watched to the end of the video, just take some time. Just look at one ticker. Go do some due diligence on one of these tickers google News ticker.

Search it and see what some of the press releases are, what some of the analysts are saying, some of the things that are being pointed out just so that you have an idea of at least what's going on with some of these companies. The thing is that once you start researching some of these companies, and once you start reinforcing the knowledge that I present in these videos with your own effort, you start getting little connections in your brain that tell you how to do it again in the future when you don't have me. I hate, hate, hate, the idea that some people just watch these videos and maybe they gloss over some of the strategies and they just hear the tickers and then they just start buying them. Or they don't buy them.

They just kind of watch it and just sort of sit on the sidelines and do nothing. And yeah, they don't lose any money, but they didn't get anything valuable from it either. Do this, not just for me, but do this for yourself. I know I will never get through to all of you, but if I get through to 10 of you, it will be totally worth it to me.

Also, if you did take the time to do some of your own due diligence on this, just go ahead and let me know in the comment section below say Charlie, I did it. That's all I want you to say That way. I know that you actually did it and that people aren't just watching this for entertainment, they're actually going and getting some educational value out of these videos. Okay folks, well to finish this off, if you have any questions, feel free to reach out to us in the comment section below.

If you are looking to learn how to trade, if you're looking to be forged into a trader, we do have Ziptrader U, which is still 50 off if you type in coupon code stay Home 2020. And lastly, if you're wondering what broker to trade these stocks on and you'd like two free stocks for signing up with a free broker, then Weeble is in the link below. Anyways, folks have a great day and I'll see you in the next video.